【耳鼻喉科-指南】英文版-中国头颈部鳞癌综合治疗专家共识（2013版）.pdf

part of 1635Future Oncol. (2014) 10(9), 1635–1648 1635ISSN 1479-6694doi:10.2217/FON.14.44 © 2014 Future Medicine Ltd ABSTRACT: Head and neck cancer is the sixth most common malignant tumor worldwide, and squamous cell cancer of the head and neck accounts for more than 90% of head and neck cancers. In China, the incidence of oral cavity and pharyngolaryngeal cancer is 3.28 per 100,000 with a mortality of 1.37 per 100,000, and the incidence of nasopharyngeal cancer is 3.61 per 100,000 with a mortality was 1.99 per 100,000. In 2013, an expert consensus conference was held in China with the aim of establishing the optimum multimodality treatments that are applied in Chinese patients with squamous cell cancer of the head and neck. The experts, who met to review the literature and discuss and modify treatment strategies used in clinical practice in China, reached a consensus on the optimum therapy approaches, which, in general, combine surgery, radiotherapy, chemotherapy and targeted therapy. The experts strongly recommended that healthcare providers should integrate proper medical resources into a collaborative group involving specialists in several disciplines to agree upon and provide the most effective therapy for individual patients. 1 Radiotherapy Department, Sichuan Cancer Hospital & Institute, South Road of Renmin Street, 4th District, No. 55, Chengdu, 610041, People’s Republic of China 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China 3 Fudan University Shanghai Cancer Center, 270 Dongan Road, Shanghai, 20003, People’s Republic of China 4 Sun Yat-Sen University Cancer Center, No. 651 Dongfeng Dong Road, Guangzhou, 510060, People’s Republic of China 5 Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, ZhiZaoju Road, No. 639, Shanghai, 200011, People’s Republic of China *Author for correspondence: langjy610@163.com ‡ Authors contributed equally Comprehensive